US Transdermal Patch Market Outlook 2020 Report

“US Transdermal Patch Market Outlook 2020” Report Highlights:

* US Transdermal Patch Market Overview
* Generic & Branded Transdermal Patches
* US Transdermal Patch Market: Value Chain Analysis
* US Transdermal Patch Contract Manufacturing Organization
* US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
* US Transdermal Patch Clinical Pipeline: 55 Patches
* Majority Patches in Preclinical Phase: 23 Patches
* Marketed Transdermal Patch Clinical Insight by Company & Indication
* Marketed Transdermal Patches in US: 32 Patches

Download Report Sample Weblink:

https://www.kuickresearch.com/report-US-Transdermal-Patch-Market-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Transdermal Patch



2. Classification of Transdermal Patches

2.1 Single/ Multiple-Layer Drug-in-Adhesive

2.2 Reservoir Transdermal Patches

2.3 Matrix Based Transdermal Patches

2.4 Vapor Patch

2.5 Active and Passive Patch



3. Why There Exist Need for Transdermal Patches?



4. Mechanism of Transdermal Patch Drug Delivery

4.1 Properties of Transdermal Therapeutics

4.2 Components of Transdermal Patch

4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch



5. Transdermal Patch v/s Traditional Drug Delivery Methods



6. US Transdermal Patch Market Overview

6.1 Current Market Scenario

6.2 US Transdermal Patch Clinical Pipeline Overview



7. Generic & Branded Transdermal Patches



8. Value Chain Analysis for Transdermal Patch Market

8.1 Research & Development

8.2 Manufacturing

8.3 Marketing & Distribution

8.4 Price to End User





9. US Transdermal Patch Contract Manufacturing Organization (CMO)



10. US Transdermal Patch Market Opportunity Assessment

10.1 Parkinson’s Disease

10.2 Alzheimer's Disease

10.3 Female Contraceptive

10.4 Nicotine Replacement Therapy

10.5 Insulin

10.6 Vaccine



11. US Transdermal Patch Market Dynamics

11.1 Favorable Market Parameters

11.2 Commercialization Challenges



12. US Transdermal Patch Market Future Prospects



13. US Transdermal Patch Clinical Pipeline by Company, Indication & Phase

13.1 Research

13.2 Preclinical

13.3 Phase-I

13.4 Phase-I/II

13.5 Phase-II

13.6 Phase-II/III

13.7 Phase-III

13.8 Preregistration

13.9 Registered



14. Marketed Transdermal Patch Clinical Insight by Company & Indication





15. Discontinued & No Development Reported in US Transdermal Patch Clinical Pipeline

15.1 No Development Reported

15.2 Discontinued

15.3 Marketed Withdrawal



16. Competitive Landscape

16.1 3M Pharmaceuticals

16.2 Acrux

16.3 Agile Therapeutics

16.4 Allergan

16.5 ANI Pharmaceuticals

16.6 Antares Pharma

16.7 Bayer HealthCare Pharmaceuticals

16.8 Corium International

16.9 Chase Pharmaceuticals

16.10 DURECT Corporation

16.11 Endo Pharmaceuticals

16.12 Fempharm

16.13 Hisamitsu Pharmaceutical

16.14 Immune Pharmaceuticals

16.15 Imprimis Pharmaceuticals

16.16 Ipsen Bioscience

16.17 Johnson & Johnson

16.18 LaSalle Laboratories

16.19 Lavipharm-increase

16.20 MINRAD International

16.21 NeurogesX

16.22 Noven Pharmaceuticals

16.23 NuPathe

16.24 Nuvo Research

16.25 Novartis

16.26 Pain Therapeutics

16.27 ProStrakan

16.28 Purdue Pharma

16.29 Sanofi

16.30 Scilex Pharmaceuticals

16.31 Senju Pharmaceutical

16.32 Somerset Pharmaceuticals

16.33 Teikoku Seiyaku

16.34 Therapeutic Discovery Corporation

16.35 Transdermal Delivery Solutions Corp

16.36 UCB

16.37 Xel Pharmaceuticals

16.38 Zosano Pharma

Figure 1-1: Steps Involved in Transdermal Permeation

Figure 1-2: Ideal Properties of Transdermal Patch



Figure 2-1: Types of Commercially Available Transdermal Patch



Figure 4-1: Properties of Transdermal Therapeutics

Figure 4-2: Components of Transdermal Patch

Figure 4-3: Types of Permeation Enhancers

Figure 4-4: Schematic Representation of Iontophoresis

Figure 4-5: Mechanism of Scopolamine Transdermal Patch

Figure 4-6: Mechanism of Nicotine Transdermal Patch

Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch



Figure 5-1: Issues with Traditional Drug Delivery Methods

Figure 5-2: Advantages of Transdermal Patch

Figure 5-3: Consistent Drug Supply by Transdermal Patch



Figure 6-1: Advantages of Transdermal Patches

Figure 6-2: Disadvantages of Transdermal Patches

Figure 6-3: US - Major Reasons Behind Growth of Transdermal Patches

Figure 6-4: US - Estimated Prescription Drug Spending (USD Billion), 2015-2020

Figure 6-5: US- Transdermal Drug Delivery System Market (US$ Billion), 2015-2020

Figure 6-6: US - Estimated Prescription Transdermal Patch Market by Volume (%), 2015 & 2020

Figure 6-7: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2015

Figure 6-8: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2020

Figure 6-9: US Transdermal Patch Pipeline by Phase (%), 2016

Figure 6-10: US Transdermal Patch Pipeline by Phase (Numbers), 2016

Figure 6-11: US Transdermal Patch Pipeline by Phase (%), 2016

Figure 6-12: US Transdermal Patch Pipeline by Phase (Numbers), 2016



Figure 7-1: Requirement in Generic Transdermal Patches

Figure 7-2: Reservations for Generic Transdermal Patches

Figure 7-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch

Figure 7-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches



Figure 8-1: Basic Features of Transdermal Patch Value Chain

Figure 8-2: Steps Involved in Transdermal Patch Manufacturing



Figure 9-1: Stages of Transdermal Patch Development

Figure 9-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System

Figure 9-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System



Figure 10-1: Potential Market Segments of Transdermal Drug Delivery Systems

Figure 10-2: US - Susceptibility of Parkinson Disease among Males and Females

Figure 10-3: US - Estimated Increase in Parkinson’s Disease Incidences

Figure 10-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)

Figure 10-5: US - Parkinson’s Disease Incidences, 2015-2020

Figure 10-6: US - Estimated Sales of Neupro Patch, 2104-2020

Figure 10-7: US - Estimated Worldwide Sales of Neupro, 2014 & 2015

Figure 10-8: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2015

Figure 10-9: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2015

Figure 10-10: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2015

Figure 10-11: US - Estimated Increase in Alzheimer’s Incidences, 2015, 2025 & 2050

Figure 10-12: US - Estimated Incidences of Alzheimer’s Disease, 2015-2020

Figure 10-13: US - Exelon Patch Sales for Alzheimer s Disease, 2013 & 2014

Figure 10-14: Requirements of Female Contraceptive Transdermal Drug Delivery Systems

Figure 10-15: Benefits of Female Contraceptive Transdermal Drug Delivery System

Figure 10-16: US - Expected Revenues Generated by Xulane Patch (US$ Million), 2015-2020

Figure 10-17: US - Decrease in Number of Smokers due to Nicotine Patch, 2005 & 2013

Figure 10-18: Factors Responsible for Increased Consumption of Nicotine Patches

Figure 10-19: Rank of US among Different Diabetes Prone Countries

Figure 10-20: US - Estimated Increase in Diabetes Incidences, 2015-2020

Figure 10-21: Benefits of Insulin Transdermal Patch

Figure 10-22: Drawback of Insulin Transdermal Patch

Figure 10-23: Benefits of Vaccine Transdermal Patch

Figure 10-24: Drawbacks of Vaccine Transdermal Patch

Figure 10-25: US - Estimated HIV Incidences, 2015-2020



Figure 11-1: Transdermal Patch Market Favorable Factors

Figure 11-2: Transdermal Patch Market Commercialization Challenges



Figure 16-1: Acrux Clinical Pipeline

Figure 16-2: Agile Therapeutics Clinical Pipeline

Figure 16-3: Antares Pharma Clinical Pipeline

Figure 16-4: Corium International Clinical Pipeline

Figure 16-5: Durect Corporation Clinical Pipeline

Figure 16-6: Endo Pharmaceuticals Clinical Pipeline

Figure 16-7: Immune Pharmaceuticals Clinical Pipeline

Figure 16-8: Novartis Clinical Pipeline

Figure 16-9: Senju Pharmaceuticals Clinical Pipeline

Figure 16-10: Xel Pharamaceuticals Clinical Pipeline

Figure 16-11: Zosano Pharma Clinical Pipeline





Table 4-1: Transdermal Patches for Various Disease Indications



Table 6-1: Features Required in Transdermal Patches

Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market



Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches

Table 7-2: US - Some Generic Transdermal Patches Available in Market



Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis



Table 10-1: US - Estimated Adoption Rates for Parkinson s Disease Transdermal Patches , 2015-2020

Table 10-2: Description of Neupro Patch for Parkinson’s Disease

Table 10-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer s Disease, 2015-2020

Table 10-4: Transdermal Patches for Alzheimer’s Disease

Table 10-5: Description of Ortho Evra Contraceptive Patch

Table 10-6: Difference Between Generic & Branded Transdermal Contraceptive Products

Table 10-7: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2015-2020

Table 10-8: US-Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2015-2020



Table 16-1: Pain Therapeutics Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.